Skip to main content
OpenTrials
Completed

NCT Number: NCT06214910

ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa

This study will compare community-delivered, multi-month dispensing of tuberculosis preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of South African adults who are recommended to receive TB preventive therapy.

We hypothesize that persons receiving multi-month dispensing of TPT in the community will have a higher rate of TPT completion at 3 months than persons receiving TPT via standard of care with monthly clinic-based refills.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Human Sciences Research Council

Sweetwaters, KwaZulu-Natal, South Africa

About this study

The research objective is to understand and overcome key barriers to tuberculosis preventive therapy (TPT) delivery and completion in South Africa in the setting of 3HP scale-up. (3HP: short-course TPT consisting of 3 months weekly isoniazid[H] plus rifapentine [P]). The study will investigate these factors through a trial comparing community-delivered TPT, to clinic-based TPT and qualitative research investigating barriers to TPT completion and exploring task-shifted TPT delivery.

Aim 1: To determine the effect of community-based initiation and delivery of TPT on TPT completion.

Hypothesis: Community-delivered TPT will be associated with higher initiation and completion of TPT than standard of care clinic-based TPT.

Approach: Persons eligible for TPT will be identified through the Triage+ TB study and other community-based TB screening activities. Eligible persons will be randomized at the household level to 1) Immediate initiation of TPT & full 12 weeks delivery at once, or 2) Immediate initiation of TPT, 2-week supply, and referral to clinic for TPT completion. TPT adherence and completion will be measured by a combination of self-report, pill count, and serum drug level indicators.

Aim 2: To determine factors associated with TPT initiation and completion in people eligible for TPT identified in community settings.

Hypothesis: People with HIV (PWH) will have better rates of initiation and completion of TPT than people without HIV.

Approach: Participant interviews and surveys at baseline and end-of-study will assess willingness to take TPT, barriers and facilitators for individuals, experience taking TPT, and experience of interactions in clinic settings. Focus groups will be purposively selected based on end-of-study survey responses to elicit factors determining patient experience.

Aim 3: To determine feasibility and acceptability of differentiated service delivery (DSD) approaches, including task-shifting, for TPT delivery and scale-up.

Hypothesis: DSD TPT will be feasible and acceptable. Approach: Participatory qualitative research, and implementation science approaches including workflow mapping will be used to assess clinician-level barriers and inefficiencies in providing clinic-based TPT. In-depth interviews and focus groups will be conducted with pharmacy assistants, nurses, clinic operational managers, and district program managers to assess acceptability. Clinic flow will be mapped to determine effect of task-shifted pharmacy assistant TPT delivery on workflow and patient experience in the clinic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 years of age
  • Living in the study catchment area
  • Eligible for TPT according to South African National guidelines(5), i.e. are a) living with HIV or b) are a close contact of a person with TB disease (defined by a person that resides in the same house as a person with TB), c) and in either case
  • Have screened negative for TB disease in the last 6 months, through TB TRIAGE+ Trial, other household contact tracing, or other community TB screening
  • Negative TB screening at enrolment (if TB TRIAGE+ screening was more than 3 months ago)
  • Willing and able to provide written or verbal consent
  • Participants whom have not received TPT in the last 12 months; this was confirmed verbally with participants during the enrolment process.

Exclusion criteria

  • Less than 18 years of age.
  • Pregnant or planning on pregnancy within next three months
  • Planning on moving or relocating from the area within the next three months
  • Positive for active TB
  • Currently on TB treatment

Treatment and study plan

Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)

Other

Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment.

Clinic-link TPT

Other

Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills).

Primary outcomes

  1. Completion of a Course of TB Preventive Therapy (TPT)

    Time frame: 3 months, extended to 16 weeks as needed

    TPT completion defined as taking 11 doses of 3HP (3 months weekly isoniazid [H] plus rifapentine [P] ) within 16 weeks of 3HP initiation. The outcome is measured as a composite outcome including: self-report of doses taken, periodic pill counts, one-time serum drug level of isoniazid. (Eight participants with contraindication to 3HP received 6H TPT. Completion of 6H was defined as taking 24 weeks within 9 months)

  2. Number of TPT Doses by Week 16

    Time frame: Enrollment to week 16

    The number of TPT doses taken by week 16

Secondary outcomes

  1. Overall Adherence With TPT

    Time frame: 3 months, extended to 16 weeks as needed

    Number of doses taken by 16 weeks (N= 8 participants received 6H TPT excluded from this analysis)

  2. Participant Satisfaction With the Assigned TPT Delivery Method

    Time frame: 3 months, extended to 16 weeks as needed

    Number of participants who answered "somewhat motivated" or "very motivated" to take TPT in exit questionnaire

  3. Adverse Events

    Time frame: 3 months, extended to 16 weeks as needed

    Assessed by adverse event reporting

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Human Sciences Research Council
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Acronym: ThiPhiSA

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 22, 2024
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.